NCT04886869 is a NA clinical trial of caffeine in Autonomic Nervous System Imbalance, sponsored by LMU Klinikum.

Who is sponsoring NCT04886869?

NCT04886869 is sponsored by LMU Klinikum.

What drugs are being tested in NCT04886869?

Interventions in NCT04886869: caffeine.

What condition does NCT04886869 study?

NCT04886869 studies Autonomic Nervous System Imbalance.

Is NCT04886869 still recruiting?

NCT04886869 is currently completed. Last updated 6 March 2026.

Last reviewed 2026-03-06 · How we verify

NCT04886869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Caffeine and the Autonomic Nervous System

Completed NA Last updated 6 March 2026

What this trial tests

NA trial testing caffeine in Autonomic Nervous System Imbalance in 20 participants. Completed in 30 June 2021.

Timeline

1 April 2021

Primary endpoint
30 June 2021

30 June 2021

Quick facts

Lead sponsor	LMU Klinikum
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	1 April 2021
Primary completion	30 June 2021
Estimated completion	30 June 2021
Sites	1 location across Germany

Drugs / interventions tested

caffeine (caffeine) — full drug profile →

Conditions studied

Autonomic Nervous System Imbalance — all drugs for Autonomic Nervous System Imbalance →

Sponsor

LMU Klinikum — full company profile →

Who can join

18 and older, any sex, with Autonomic Nervous System Imbalance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Caffeine consumption has been linked to dysfunction of the autonomic nervous system. In this study the investigators analyze the effects of caffeine containing drinks (including energy drinks and coffee) on ECG based parameters of the autonomic nervous system.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of energy drink versus coffee consumption on periodic repolarization dynamics: an interventional study.
Schüttler D, Rudi WS, Bauer A, Hamm W, et al · · 2022 · cited 5× · PMID 35266046 · DOI 10.1007/s00394-022-02853-8

Verify or expand the search:

Other trials of caffeine

Trials testing the same drug.

NCT07412951 — Effects of Caffeine and Shot Put Performance · NA · active not recruiting
NCT06638372 — Caffeinated Chewing Gum on Special Forces Performance · NA · completed
NCT06758336 — Caffeinated Chewing Gum & Wrestling Performance · NA · completed
NCT06430996 — Caffeinated Chewing Gum on 400-meter Performance · NA · completed
NCT06431035 — Caffeine & Bodybuilding Dehydration Ability · NA · completed

Other recruiting trials for Autonomic Nervous System Imbalance

Currently open trials in the same condition.

NCT06359808 — Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis · recruiting
NCT05212129 — Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome · NA · recruiting

Other LMU Klinikum trials

Trials by the same sponsor.

NCT07072676 — The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Train · NA · enrolling by invitation
NCT07159607 — Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR) · recruiting
NCT06600165 — Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma · recruiting
NCT07460531 — Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure · recruiting
NCT06605612 — Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04886869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LMU Klinikum
Last refreshed: 6 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04886869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing